[Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in patients with hepatitis C virus-related hepatocellular carcinoma].
To evaluate the prognostic significance of serum GGT in patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC) treated with transcatheeter arterial chemoembolization (TACE). The clinicopathological data of 110 patients with hepatitis C virus-related stage B hepatocellular carcinoma, who received TACE treatment from January 2008 to May 2011, were retrospectively analyzed. The patients were divided into two groups: the normal GCT group (GGT<50 U/L, 41 cases) and high GCT group (GGT≥50 U/L, 69 cases). The Kaplan-Meier method was used to analyze the survival rates, log-rank test was used for univariate analysis, and Cox regression model was used for multivariate analysis. The factors affecting survival and prognosis of the patients were analyzed. The pretreatment GGT level was (160.0±120.2) U/L in the high GGT group and (40.1±8.5) U/L in the normal GGT group (P<0.001). After TACE treatment, the 1-, 2- and 3-year survival rates were 90.2%, 45.9% and 24.6% in the high GGT group, and 90.2%, 75.6% and 58.5%, respectively, in the normal GGT group (P=0.002). The univariate analysis showed that the pretreatment GGT level, ECOG score, α-fetoprotein, tumor size, tumor number, and Child grade are factors affecting the prognosis of HCV-related hepatocellular carcinoma patients (P<0.05 for all). The Cox multivariate survival analysis revealed that the tumor size, tumor number, Child grade, and serum GGT level are independent prognostic factors for patients with stage B HCV-related hepatocellular carcinoma. The level of serum GGT before TACE is an independent prognostic factor for patients with stage B HCV-related hepatocellular carcinoma.